Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution.

Venkatesan S, Rosenthal R, Kanu N, McGranahan N, Bartek J, Quezada SA, Hare J, Harris RS, Swanton C

Ann. Oncol. 29 (3) 563-572 [2018-03-01; online 2018-01-13]

The apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) mutational signature has only recently been detected in a multitude of cancers through next-generation sequencing. In contrast, APOBEC has been a focus of virology research for over a decade. Many lessons learnt regarding APOBEC within virology are likely to be applicable to cancer. In this review, we explore the parallels between the role of APOBEC enzymes in HIV and cancer evolution. We discuss data supporting the role of APOBEC mutagenesis in creating HIV genome heterogeneity, drug resistance, and immune escape variants. We hypothesize similar functions of APOBEC will also hold true in cancer.

Affiliated researcher

QC bibliography QC xrefs

PubMed 29324969

DOI 10.1093/annonc/mdy003

Crossref 10.1093/annonc/mdy003

4792954

pmc PMC5888943